Format

Send to

Choose Destination
Future Oncol. 2011 Jul;7(7):827-39. doi: 10.2217/fon.11.57.

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.

Author information

1
NCIC Clinical Trials Group, 10 Stuart St, Queen's University, Kingston, ON, K7L 3N6, Canada.

Abstract

Ridaforolimus (deforolimus; AP23573; MK-8669) is a novel sirolimus derivative manufactured by ARIAD Pharmaceuticals and acquired by Merck. It is a small-molecule kinase inhibitor of the mTOR in clinical development for the treatment of cancer. Both intravenous and oral formulations of the agent are being tested in cancer clinical trials. In preclinical and clinical studies, ridaforolimus exhibited significant antitumor activity with acceptable safety and tolerability. With single-agent ridaforolimus, mucositis and myelosuppression were dose-limiting toxicities. In advanced soft-tissue sarcoma, single-agent ridaforolimus was associated with a 29% clinical benefit rate and 2% partial response rate. A Phase III trial has recently been reported to have met its primary end point.

PMID:
21732754
DOI:
10.2217/fon.11.57
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center